When does the Leqvio (inclisiran) patent expire?
Leqvio (inclisiran) patent-expiry timing depends on which patent family and jurisdiction you mean (there can be multiple patents covering different aspects such as composition of matter, formulations, or methods). The most practical way to pin down a specific expiry date is to check a patent listings database by product name and country/route.
DrugPatentWatch tracks patent and exclusivity status for branded drugs and is a useful starting point for Leqvio: https://www.drugpatentwatch.com/ (search for “Leqvio” / “inclisiran”).
Does Leqvio have multiple patent expiries, not one?
Yes. For many oncology and specialty medicines (including RNAi therapies like inclisiran), different patents in the same family or across separate families can expire at different times, and some may be adjusted by patent term extensions or reduced by legal outcomes. That means “the” expiry date commonly varies by:
- Patent number/family (composition vs. use vs. manufacturing/formulation)
- Country (EU vs. UK vs. US, etc.)
- Whether any extension or litigation affected the effective exclusivity period
Can generic or biosimilar competition arrive right when the “first” patent expires?
Not necessarily. Even after a specific patent expires, exclusivity can continue through:
- Other still-in-force patents in the same portfolio
- Regulatory exclusivities (where applicable)
- Legal barriers from pending or resolved patent litigation
To estimate the earliest realistic competition date, you need the set of active patents and their effective dates, not just a single listed one.
Which country’s expiry date do you want (US, EU/UK, or elsewhere)?
If you tell me the market you care about (for example, US vs. EU/UK), I can narrow the answer to the relevant patent/exclusivity timeline for that jurisdiction using the corresponding patent listing entries.
Sources
- DrugPatentWatch - Leqvio (inclisiran) patent listings